Testing IKS03 for advanced B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell non-Hodgkin lymphoma (like diffuse large B-cell, follicular, or mantle cell lymphoma) that has come back or not responded to at least two previous treatments.
- Your lymphoma cells have a protein called CD19 on their surface (this may be tested).
- You are in good enough physical condition to be up and about (ECOG performance status 0 or 1).
- You agree to use effective contraception if you or your partner could become pregnant, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.